BioSpace News Archive

The Medicare Physician Fee Schedule proposed rule released by the Centers for Medicare & Medicaid Services for calendar year 2021 jeopardizes patient care, specifically surgical care.

Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, today provided an update on the development of the previously announced potential medical solution utilizing nanobody technology for both detection and treatment of COVID-19 in

JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral A

Study published in Molecular Cancer Therapeutics HSP90 targeting drives high tumor uptake and retention of a pan-PI3K inhibitor payload Lead conjugate shows xenograft efficacy superior to non-targeted pan-PI3K inhibitor Tumor targeting and payload masking prevent hyperglycemia seen with other PI3Kα inhibitors

The highly-respected healthcare industry veteran will bring his signature team building skills, track record of double-digit revenue growth and subject matter expertise in diabetes. CHARLOTTE, N.C.--( BUSINESS WIRE )-- Monarch Medical Technologies, maker of the EndoTool® Glucose Management System, today announced that Raymie McFarland will serve as its new President & Chief Executive Officer. McFarland has been deeply entrenched in the diabetes te

Halberd Corp. announced that they have secured non-dilutive, grant-based funding for their patent pending Covid-19 treatment.

3M announced that Jeffrey R. Lavers is appointed executive vice president, Consumer Business Group, effective immediately.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Seismic Bio, Inc., an immuno-oncology company focused on bispecific antibody development, today announced a partnership for the discovery and optimization of antibodies to high-value immuno-oncology targets. “With its advanced Hyperimmune L

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that it will hold virtual presentations at the following upcoming investor conferences:

Establishes new line of business, adds recurring revenue stream while more than doubling dermatology customer base across the state